• Patient age 18 years or older, both sexes.

• Clinical diagnosis of MPM at enrolling institution.

• Prior to randomization, intraoperative pathologic confirmation of epithelioid MPM at enrolling institution.

• Complete or near-complete CRS achieved.

• Patient must be planning to undergo complete cytoreduction of all peritoneal disease.

• ECOG performance status ≤ 1.

• Hematology: ANC ≥ 1,500/µl.

• Platelets \> 75,000/µl.

• Adequate renal function: creatinine \< 1.5× the upper limit of normal (ULN) or calculated creatinine clearance of ≥50 ml/min.

• Adequate hepatic function: bilirubin \< 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin \< 3.0 mg/dL).

• Women of childbearing potential with a negative pregnancy test result (urine or blood) who agree to use an effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.

• A man participating in this study must agree to utilize a reliable barrier form of contraception for the duration of the study

• Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.